Lead by proven industry experience, Marvel is at the forefront of modern science.
We are a life sciences company whose primary focus is the discovery and the development of a synthetic derivative compound of a known proven drug. Our business model capitalizes on significantly lower cost, less time and a lower risk profile to bring a drug asset to commercialization faster than the traditional long-term biotech model.
The Company has been specifically focused on the discovery of new chemical entities that inhibits the A2a adenosine receptor. The A2a receptor is a target for a number of diseases representing areas of significant unmet medical needs, each with multi-billion dollar potential, and with fundamentally no competitors.

Our drug assets are targeted for the treatment of large and growing markets associated with a predominantly aging population.
The Company is targeting specifically
Neurological Diseases
that have not been treated with
conventional therapeutics
Non-Alcoholic
Steatohepatitis (NASH)
Currently no approved therapies
Cancer
Pursuing as an adjunctive
therapy
Stock Information
Shares Outstanding : 32,586,231
Insider Ownership : 12,525,098 (38.4%)
Warrant coverage : 10,071,533
Stock options granted : 2,825,000
Recent News
Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials
Calgary, Alberta (August 22, 2023)– Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has successfully completed its 4-week good...
Marvel Highlights Key Asset at the 2023 Alzheimer’s Association International
Calgary, Alberta – (July 10, 2023) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to announce that it has been selected to present the Company’s scientific...


Contact
Marvel Biosciences Corp.
Suite 420, 505 8th Avenue S.W.
Calgary, Alberta T2P 1G2
Marvel Biosciences
Marvel Biosciences Corp. (the “Company”) is a life sciences company whose primary focus is the discovery and the development of a synthetic derivative compound of a known proven drug.